(GMRE) Global Medical REIT - Ratings and Ratios
Healthcare Facilities, Medical Properties, Real Estate, Leasing, Management
GMRE EPS (Earnings per Share)
GMRE Revenue
Description: GMRE Global Medical REIT
Global Medical REIT Inc. (GMRE) is a net-lease medical real estate investment trust that specializes in acquiring healthcare facilities and leasing them to reputable healthcare providers, including physician groups and regional and national healthcare systems, generating stable rental income.
As a Health Care REIT, GMREs business model is centered around providing essential healthcare infrastructure to medical professionals, allowing them to focus on delivering quality patient care. With a diverse portfolio of properties, GMRE is positioned to benefit from the growing demand for healthcare services in the United States.
From a technical analysis perspective, GMREs stock price has been trending downwards, with the current price of $6.19 being significantly lower than its 52-week high of $9.22. The stock is currently trading slightly above its 20-day Simple Moving Average (SMA) of $6.16, indicating a potential stabilization. However, the 50-day SMA and 200-day SMA are still trending downwards, suggesting a longer-term bearish trend.
Using a combination of technical and fundamental analysis, we can forecast that GMREs stock price may experience a short-term bounce if it can sustain its current level above the 20-day SMA. However, the high P/E ratio of 209.67 and relatively low Return on Equity (RoE) of 1.48% may indicate underlying fundamental challenges. Assuming the company can maintain its current dividend yield and continue to grow its rental income, a potential price target could be around $7.50, representing a 21% increase from current levels. However, this would require a significant improvement in the companys earnings and a reversal of the current bearish trend.
Investors should closely monitor GMREs future earnings reports and watch for any changes in the companys guidance or outlook. Additionally, a sustained move above the 50-day SMA of $6.73 could be a bullish indicator, potentially paving the way for further gains.
Additional Sources for GMRE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
GMRE Stock Overview
Market Cap in USD | 942m |
Sector | Real Estate |
Industry | REIT - Healthcare Facilities |
GiC Sub-Industry | Health Care REITs |
IPO / Inception | 2016-06-29 |
GMRE Stock Ratings
Growth Rating | -35.7 |
Fundamental | 12.1 |
Dividend Rating | 73.3 |
Rel. Strength | -22.5 |
Analysts | 3.9 of 5 |
Fair Price Momentum | 7.24 USD |
Fair Price DCF | 5.06 USD |
GMRE Dividends
Dividend Yield 12m | 10.15% |
Yield on Cost 5y | 10.22% |
Annual Growth 5y | 0.98% |
Payout Consistency | 95.6% |
Payout Ratio | % |
GMRE Growth Ratios
Growth Correlation 3m | -39.7% |
Growth Correlation 12m | -79.3% |
Growth Correlation 5y | -61.7% |
CAGR 5y | -0.43% |
CAGR/Max DD 5y | -0.01 |
Sharpe Ratio 12m | -1.00 |
Alpha | -25.24 |
Beta | 0.534 |
Volatility | 25.53% |
Current Volume | 470.7k |
Average Volume 20d | 759.7k |
Stop Loss | 6.9 (-3.2%) |
As of July 12, 2025, the stock is trading at USD 7.13 with a total of 470,657 shares traded.
Over the past week, the price has changed by +0.14%, over one month by +14.53%, over three months by +4.54% and over the past year by -16.09%.
Neither. Based on ValueRay´s Fundamental Analyses, Global Medical REIT is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 12.14 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GMRE is around 7.24 USD . This means that GMRE is currently overvalued and has a potential downside of 1.54%.
Global Medical REIT has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy GMRE.
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, GMRE Global Medical REIT will be worth about 7.9 in July 2026. The stock is currently trading at 7.13. This means that the stock has a potential upside of +10.8%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 9.1 | 27.5% |
Analysts Target Price | 10.2 | 42.5% |
ValueRay Target Price | 7.9 | 10.8% |